key: cord-0325946-umtpsnwz authors: O’Rourke, Brian; Nguyen, Sunny; Tilles, Arno W.; Bynum, James A.; Cap, Andrew P; Parekkadan, Biju; Barcia, Rita N. title: Mesenchymal Stromal Cell Delivery via an Ex Vivo Bioreactor Preclinical Test System Attenuates Clot Formation for Intravascular Application date: 2020-11-24 journal: bioRxiv DOI: 10.1101/2020.11.20.391631 sha: b38795f2e3f490c60fd5ce678ca38180c45038a7 doc_id: 325946 cord_uid: umtpsnwz While mesenchymal stromal cells (MSCs) are an appealing therapeutic option for a range of clinical applications, their potential to induce clotting when used systemically remains a safety concern, particularly in hypercoagulable conditions, such as in patients with severe COVID-19, trauma, or cancers. Here, we tested a novel ex vivo approach aimed at improving the safety of MSC systemic administration by use of a bioreactor. In this device, MSCs are seeded on the outside of a hollow-fiber filter, sequestering them behind a hemocompatible membrane, while still maintaining cross talk with blood cells and circulating signaling molecules. The potential for these bioreactor MSCs to induce clots in coagulable plasma was compared against “free” MSCs, as a model of systemic administration, which were directly injected into the circuit. Our results showed that physical isolation of the MSCs via a bioreactor extends the time necessary for clot formation to occur when compared to “free” MSCs. Measurement of cell surface data indicates the presence of known clot inducing factors, namely tissue factor and phosphatidylserine. Results also showed that recovering cells and flushing the bioreactor prior to use further prolonged clot formation time. Further, application of this technology in two in vivo models did not require additional heparin to maintain target ACT levels relative to the acellular device. Taken together, the use of hollow fiber filters to house MSCs, if adopted clinically, could offer a novel method to control systemic MSC exposure and prolong clot formation time. Mesenchymal stromal cells (MSCs) are potent immunoregulators with strong preclinical data that 53 support their application in a wide range of clinical conditions [1] [2] [3] [4] . MSCs can provide therapeutic 54 benefit to patients suffering from systemic inflammation by effectively immunomodulating peripheral 55 blood cells to reduce inflammatory signaling and promote homeostasis. Significant evidence of these 56 MSC derived effects have been shown in vitro, in animal models, and in clinical trials, including recently evaluated, including shifting delivery of the MSCs from intravenous to intramuscular administration, 82 emphasizing higher cell viability, or even using gene modification to promote cell survival [28] [29] [30] [31] . 83 We propose an alternative approach which would minimize direct exposure of the MSCs to blood and 84 contain MSCs in one location. We utilized a recently described perfusion platform that incorporates a 85 hollow-fiber filter into a fluid circuit to compartmentalize the MSCs, while still allowing exchange of 86 signaling molecules from perfusate to cells, and vice-versa [32] . MSCs within this platform were shown 87 to effectively retain their immunomodulatory capacity and alter perfused lymphocyte proliferation, 88 activation, and cytokine production in an MSC dose and duration exposure dependent manner, despite 89 having minimal direct contact with the blood cells. 90 Benchtop coagulation assays, including microfluidic setups, are becoming increasingly translationally 91 relevant [33] . Here, we used a MSC bioreactor platform to assay whether limiting the direct exposure of 92 fresh frozen pooled plasma from healthy patients to MSCs, and therefore the available tissue factor and 93 phosphatidylserine of the MSCs, would affect clot formation time (CFT) in a modified plasma-based clot 94 formation assay [34, 35] . Plasma was perfused through bioreactors seeded with MSCs as well as through 95 circuits in which cells were directly injected into the perfused plasma to make comparative CFT 96 measurements. We were able to show that bioreactor use significantly prolonged CFT relative to direct 97 injection of the MSCs. Flushing of concentrated soluble factors from bioreactors further contributed to 98 prolonged CFTs. Lastly, the previously proposed clinical solution for MSC driven clot formation, 99 anticoagulation with heparin [36] [37] [38] [39] , was shown to be effective in both perfusion setups. These results 100 suggest this new modality for systemic MSC delivery may offer a safer alternative to intravenous MSC 101 injection. The clinically scaled ex vivo engineered MSC delivery is currently undergoing testing in a Phase 102 I/II trial in acute kidney injury (AKI) and COVID-19 associated AKI. 103 MSCs were thawed from cryopreservation into citrated fresh-frozen pooled plasma (FFPP) (George King 116 Bio-Medical, KS, USA) and counted via Trypan Blue exclusion. Each direct injection subgroup was 117 processed individually and subgroups were never combined. The fresh thawed direct injection subgroup 118 was placed into plasma after counting and directly injected for perfusion ( Figure 2 ). The recovered direct 119 injection subgroup allowed for 24 hours of recovery on a cell culture dish, followed by dissociation with 120 TryPLE, counting via Trypan Blue exclusion, and placing into plasma prior to direct injection. Cells for use 121 in washed groups were washed with saline directly after thaw, pelleted and resuspended in fresh 122 citrated media prior to direct injection. 123 124 Bioreactor Fill/Finish MSCs were thawed from cryopreservation into aMEM supplemented with 10% HSA and counted via 126 Trypan Blue exclusion prior to seeding in device. The desired cell number was suspended into 9 mL of 127 aMEM and then seeded into saline-primed microreactors (Spectrum Laboratories, CA, USA; C02-P20U-128 05) with 0, 1, or 3 ×10 6 viable cells per device (0M, 1M, 3M, respectively). Excess media flowed through 129 the semi-permeable hollow fibers while cells remained within the extraluminal space of the reactor. 130 Microreactors used were 20 cm long with an internal surface area of 28 cm 2 . Within each microreactor 131 are nine 0.5 mm diameter fibers comprised of polyethersulfone with a 0.2 μm pore size. The total 132 internal volume of the microreactor is 1.5 mL. 133 Depending on the group, microreactors were either used immediately or incubated at 37℃ for 2 hours 134 to allow for cell attachment and were subsequently held for24 hours at room temperature prior to 135 integration into the circuit. This hold time intends to mimic the time between device manufacture and 136 potential clinical application. 137 Development of an assay to test CFT under perfusion 218 We developed an approach in which we could test human plasma compatibility of allogeneic MSCs 219 across multiple extents of cell exposure. Cryopreserved MSCs could either be injected into the plasma 220 directly after thaw (Fig. 1A) , cultured for 24 hours after recovery and then directly injected into plasma 221 ( Fig. 1B) , or seeded into hollow-fiber microreactors with a semi-permeable membrane, allowed to 222 attach, and held for up to 24 hours before being subjected to perfusion (Fig. 1C) . These ranges of 223 administration broadly represent many of the systemic administration options available today and allow 224 the comparison of varying degrees of MSC to plasma exposure and the effects of MSC culture 225 conditions. 226 After perfusion, plasma was collected from the circuit via the syringe port and placed into microwells for 227 spectrophotometric reading over time. The point at which a clot was formed was determined by using 228 the resultant spectrophotometric readout and formula (Fig. 1D, E) showed that the presence of MSCs accelerated clot formation under flow conditions relative to acellular 235 controls (Figure 2) . Interestingly, the same experimental setup run with plasma isolated from an individual donor 24 hours after collection instead of FFPP did not result in significantly different clotting 237 times between cellular and acellular groups, likely as it wasn't frozen directly after being pulled (Figure 238 S1 ). Spectrophotometric measurements of optical density at 405 nm captured fibrin clot formation as it 239 occurred within the microwell via increases in measured OD over time (Figure 2A) suggesting that washing to remove debris and cryopreservative did not affect clot time. However, CFT 262 was significantly prolonged by allowing for 24 hours of recovery in culture prior to injection (Figure 3B) . 263 As levels of MSC surface markers appeared to be correlated with clot initiation, we next asked whether 264 limiting the direct interaction of MSC surface markers and plasma could reduce the rate of clot 265 formation. Interestingly, recovery of MSCs within a microreactor did not significantly affect measured 266 CFTs relative to fully recovered MSCs ( Figure 3B ). MSCs that were thawed, seeded into MRs, and 267 immediately perfused, clotted at the same time as MSCs that were seeded and allowed to recover for 24 268 hours. These results suggest that though recovery of cells post thaw significantly reduces MSC induced 269 clotting, housing them in an adherent state on the outside of a hollow fiber seems to further, and more 270 significantly, reduce their clotting potential even without any recovery period. (Figure 6 A) . AMI was induced, animals were re-perfused/stabilized for 1 hour and then connected to 311 the bioreactor perfusion circuit for 12 hours. All animals were perfused without events for 12 hours, 312 with each group showing cardiac injury biomarker induction (Figure 6 B) and similar infarct size (Figure 6 313 C) . Heparin was administered throughout the perfusion process to maintain a minimum activated 314 clotting time (ACT) of at least 300 seconds (as mandated by IACUC), with neither group requiring 315 significantly more heparin than the other (Figure 6 D, E) . These data support Here, in concert with the previously mentioned improvements with cellular production, we assayed the 341 value of incorporating an experimental setup which confines MSCs behind the membrane of a hollow-342 fiber filter. Given that much of the MSCs' ability to induce clot formation arises from its cell surface 343 markers and secreted vesicles, we considered that the confinement of the cells and their procoagulant 344 expressing surface markers in one extraluminal location may reduce the rate at which clot formation 345 occurs. We used an existing bioreactor platform known to retain MSC immunomodulatory capacity in 346 combination with modifications to an existing clot formation assay to assess cellular effect on CFT in this 347 immobilized state relative to direct injection [32, 34, 35] . Through this platform we perfused citrated, 348 platelet poor fresh-frozen pooled plasma. This plasma contains many essential factors for clot initiation, 349 including prothrombin which can be activated with the addition of calcium via CaCl2 to form firm clots 350 over time. Immediately after CaCl2 addition, this coagulable (but still liquid) plasma is perfused through the hollow-352 fiber filter platform. As expected, direct injection of MSCs into the coagulable plasma perfusion circuit 353 led to rapid clot formation in a dose-dependent manner. Interestingly, perfusion of coagulable plasma 354 through bioreactors seeded with MSCs resulted in clotting at rates significantly slower than their 355 comparable direct injection groups, suggesting that free, circulating MSCs increase thrombosis risk more 356 than bioreactor immobilized MSCs. Like the direct injection group, the MSC dose seeded in the 357 bioreactor was predictive of CFT with higher doses inducing quicker clots, likely through the increased 358 production of pro-coagulable MSC factors. It is also important to note that the presence of a filter 359 Having shown that cell presence shortens clot formation time we sought to use the platform to mitigate 377 that effect as much as possible. Since our microreactor is composed of hollow fibers, exchange does 378 happen through the 0.2 μm pores on the fibers in the microreactor. During hold, MSCs continue to 379 produce materials and some of this accumulated material could be contributing to clot formation. To 380 assess this, we developed a flush protocol and measured steep drops in known coagulation markers. 381 Consequently, flushing resulted in slower CFTs at higher MSC doses. Future studies will assay whether 382 flushing also affects immunomodulatory potential relative to unflushed reactors [32] . 383 Despite the microreactors measured effect of prolonging CFT, it did not completely abrogate the cellular 384 contribution to shortened CFT. In clinical setting anticoagulation protocols will likely be integrated to 385 ensure designated perfusion times are met. Our in vitro experiments and in vivo canine studies showed 386 that heparin administration could effectively prevent any cellular induced clot formation during 387 perfusion. However, many of the patients suffering from systemic inflammation, including those with 388 COVID-19, present with hypercoagulable plasma that will require anticoagulation prior to MSC 389 administration. Our pig model represented a more physiologically relevant condition in which inflamed 390 animals were perfused with a device scaled for human use. Under these acute injury conditions, no 391 clotting was observed in animals perfused with devices loaded with 750M MSCs and for 12 hours. The 392 lack of additional heparin requirement suggests that patients set to undergo MSC-bioreactor perfusion 393 may not need more heparin than a sham control undergoing the same procedure. Future studies 394 comparing direct infusion of MSCs to bioreactor housed MSCs would be useful to evaluate both for 395 coagulation and efficacy responses. Given the slower CFT in the microreactor groups relative to the direct injection groups, it is possible that 397 a lower dose of heparin could be administered to the microreactor groups. Future dose testing will be 398 required to verify this. Such a finding would be clinically relevant, as reduction in the amount of heparin 399 required to be delivered to critically ill patients may help prevent unintended health consequences. compared to historical controls [57] . The novel delivery approach described here could potentially 413 reduce risk of clot formation from IV administered MSCs, making treatment potentially safer and more 414 controlled than direct infusion. 415 We conclude that immobilization of MSCs in a hollow fiber filter contributes to a reduced clot initiation 417 potential relative to directly injected MSCs. Further removal of cellular byproducts through saline 418 flushing of the bioreactor further reduces the MSC based clot formation potential. Additional heparin does not appear to be required to maintain a designated ACT value relative to acellular perfusion 420 circuits. Taken together, combined integration of these approaches may make MSC therapies which 421 require systemic MSC exposure at less risk for coagulation-related events for a larger population, 422 including the hypercoagulable. The data that support the findings of this study are available from the corresponding author 438 upon reasonable request. 439 440 Meta-analysis of preclinical studies of 443 mesenchymal stromal cells to treat rheumatoid arthritis Preclinical evaluation of 445 mesenchymal stem cells overexpressing VEGF to treat critical limb ischemia Mesenchymal Stem Cells for Chronic Wound Healing: 448 Current Status of Preclinical and Clinical Studies Stem/Stromal 450 Cells for Treatment of Kidney Injuries With Focus on Preclinical Models Mesenchymal stem cells as therapeutics Concise review: mesenchymal stem cells: their 455 phenotype, differentiation capacity, immunological features, and potential for homing Mesenchymal stem cells in health and disease Mesenchymal Stromal Cells Anno 2019: Dawn of the Therapeutic Era? 460 Concise Review Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 463 pneumonia requiring mechanical ventilation. A proof of concept study: EClinicalMedicine Mesoblast's Stem Cell Therapy Shows 83% Survival in Ventilator-Dependent Thrombogenic Risk Induced by Intravascular Mesenchymal Stem 468 Cell Therapy: Current Status and Future Perspectives Effect 470 of MSCs and MSC-Derived Extracellular Vesicles on Human Blood Coagulation Familial occurrence of pulmonary 472 embolism after intravenous, adipose tissue-derived stem cell therapy Are 475 therapeutic human mesenchymal stromal cells compatible with human blood? Stem cells The role of tissue factor and factor VIIa in hemostasis Procoagulant 480 activity of human mesenchymal stem cells. The journal of trauma and acute care surgery Clinical Cellular 483 Therapeutics Accelerate Clot Formation The effects of cell type and 485 culture condition on the procoagulant activity of human mesenchymal stromal cell-derived extracellular 486 vesicles. The journal of trauma and acute care surgery Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Progress 488 in lipid research Neonatal platelet function. Seminars in thrombosis and 490 Differential roles of tissue factor and 492 phosphatidylserine in activation of coagulation Tissue factor: a key molecule in hemostatic and nonhemostatic systems MSC Therapies for COVID-19: 496 Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery 497 for Treatment Safety and Efficacy Abnormal coagulation parameters are associated with poor prognosis 499 in patients with novel coronavirus pneumonia Coagulopathy and Antiphospholipid 502 Antibodies in Patients with Covid-19 Incidence of 504 thrombotic complications in critically ill ICU patients with COVID-19 Cryopreserved 507 mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock 508 response and impaired interferon-γ licensing Mesenchymal Stromal Cell 510 Therapeutic Delivery: Translational Challenges to Clinical Application Improved therapeutics of modified 513 mesenchymal stem cells: an update A comprehensive characterisation of large-scale 515 expanded human bone marrow and umbilical cord mesenchymal stem cells Mesenchymal stromal cell therapeutic potency is dependent upon viability, route 518 of delivery, and immune match Ex Vivo Reprogramming of Human Immune Cells Microfluidic devices for studying coagulation 522 biology Development of a microplate coagulation assay for Factor V in human 524 plasma Abnormal clotting 526 of the intrinsic/contact pathway in Alzheimer disease patients is related to cognitive ability Mesenchymal Stem Cells Have Innate Procoagulant Activity and Cause Microvascular Obstruction 530 Following Intracoronary Delivery: Amelioration by Antithrombin Therapy. Stem cells Heparin improves BMSC cell therapy: Anticoagulant 533 treatment by heparin improves the safety and therapeutic effect of bone marrow-derived mesenchymal 534 stem cell cytotherapy Clinical Protocol to 536 Prevent Thrombogenic Effect of Liver-Derived Mesenchymal Cells for Cell-Based Therapies Unfractionated heparin for hemodialysis: still the best option Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic 540 Opportunities Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines Safety of cell therapy 545 with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials Biobanking of Human Mesenchymal Stem Cells: Future 548 Strategy to Facilitate Clinical Applications Trends in mesenchymal stem cell clinical trials 2004-2018: 551 Is efficacy optimal in a narrow dose range? ISEV and ISCT statement 553 on EVs from MSCs and other cells: considerations for potential therapeutic agents to suppress COVID-554 19 Mesenchymal Stromal Cell Therapy for Graft Versus Host Disease Clinical Use of Mesenchymal Stromal Cells in the Treatment 559 of Acute Graft-versus-Host Disease. Transfusion medicine and hemotherapy : offizielles Fibrinogen adsorption to biomaterials Heparin coatings for improving blood compatibility of medical devices. Advanced 564 drug delivery reviews ECMO biocompatibility: surface coatings, anticoagulation, and 566 coagulation monitoring. Extracorporeal Membrane Oxygenation-Advances in Therapy Can cells and biomaterials in therapeutic medicine be 569 shielded from innate immune recognition? Cryopreserved 571 mesenchymal stem cells regain functional potency following a 24-h acclimation period Do cryopreserved 574 mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? Innovations in CKRT: individualized therapy with fewer complications. 577 Clinical remission of a critically ill COVID-19 patient 579 treated by human umbilical cord mesenchymal stem cells: A case report Transplantation of ACE2(-) Mesenchymal Stem 581 Cells Improves the Outcome of Patients with COVID-19 Pneumonia Advisory Committee Votes Nine to One in Favor of Remestemcel-L (Ryoncil™) 583 for Efficacy in Children With Steroid-Refractory Acute Graft Versus Host Disease Figure 1 . Clot Formation Assay Experimental Setup. MSCs were thawed from cryopreservation and were either (A) immediately combined into fresh-frozen pooled plasma-based (FFPP), perfused in the circuit and read, (B) cultured for 24 hours then resuspended into FFPP, perfused in the circuit and read, or (C) seeded into micro bioreactors (MR), allowed to attach to the hollow-fiber filters for 2 hours, room temperature incubated for 24 hours then attached to perfusion circuits loaded with FFPP, perfused and read. Perfusion of the MR circuits lasted 5 minutes before samples were collected and read on the spectrophotometer at 405nm to assess fibrin formation. (D) Resulting spectrophotometric optical density (OD) readouts were graphed over time. (E) Formula used for the calculation of the clot formation time determined at the ½ maximal value. MSCs used in MR groups were first incubated for 2 hours at 37 °C followed by a 24 hour hold at room temperature prior to perfusion. After each groups' cells were prepared warmed fresh frozen pooled plasma was perfused through circuit for 5 minutes then subjected to spectrophotometric measurements. (A) Measurements of fibrin clot formation in plasma were made every 10 seconds over a 45-minute period (grey shaded region) following 5 minutes of perfusion (aqua shaded region). Groups which clotted during perfusion are designated with an 'x' at the time at which the clot was noted to be visibly obstructing perfusion. As clots formed, absorbance increased resulting in the designated curves. (B) Values for CFT were determined.Resulting values were graphed and analyzed with an unpaired student's t-test. N=3 runs per group. **=p<0.005; ***= p= 0.0005; ****= p< 0.0001. Error bars represent ± standard deviation. DI = direct injection in each respective group. MSCs for direct injection groups were thawed directly into plasma then used, while microreactor groups were seeded with MSCs and allowed to attach for 2 hours at 37 °C followed by a 24 hour hold at room temperature prior to perfusion. Innovin (thromboplastin) was added to the 0M group as a positive control. After each groups' cells were prepared, warmed FFPP was perfused through circuit for 5 minutes then subjected to spectrophotometric measurements. Measurements of fibrin clot formation in plasma were made every 10 seconds over a 45-minute period. Values for CFT were determined and resulting values were graphed and analyzed with an unpaired student's t-test. Samples which showed no increase in absorbance through the course of the experiment were designated to have not clotted. N≥2 runs per group. *= p< 0.05. Error bars represent ± standard deviation.